Immutep (IMMP) Stock Price, News & Analysis $2.09 +0.01 (+0.48%) (As of 11:13 AM ET) Add Compare Share Share Today's Range$2.05▼$2.1050-Day Range$1.76▼$2.0852-Week Range$1.50▼$3.90Volume14,346 shsAverage Volume532,747 shsMarket Capitalization$183.77 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Immutep MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside312.6% Upside$8.50 Price TargetShort InterestHealthy0.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.42) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.86 out of 5 starsMedical Sector499th out of 942 stocksPharmaceutical Preparations Industry217th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingImmutep has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Immutep has a forecasted upside of 312.6% from its current price of $2.06.Amount of Analyst CoverageImmutep has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.43% of the outstanding shares of Immutep have been sold short.Short Interest Ratio / Days to CoverImmutep has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immutep has recently decreased by 7.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmutep does not currently pay a dividend.Dividend GrowthImmutep does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMP. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Immutep to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immutep insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.07% of the stock of Immutep is held by insiders.Percentage Held by InstitutionsOnly 1.84% of the stock of Immutep is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immutep are expected to grow in the coming year, from ($0.42) to ($0.32) per share.Price to Book Value per Share RatioImmutep has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immutep Stock (NASDAQ:IMMP)Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Read More IMMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMMP Stock News HeadlinesDecember 2, 2023 | americanbankingnews.comImmutep (NASDAQ:IMMP) Share Price Crosses Above 50 Day Moving Average of $1.87November 6, 2023 | finance.yahoo.comImmutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast CancerDecember 11, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 3, 2023 | finanznachrichten.deImmutep Limited: Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNovember 3, 2023 | markets.businessinsider.comImmutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNovember 2, 2023 | finance.yahoo.comImmutep to Participate in November Investor EventsOctober 27, 2023 | markets.businessinsider.comBuy Rating for Immutep (IMMP) Supported by Strong Phase 2 Study Results and Solid Financial PositionOctober 25, 2023 | msn.comImmutep receives about A$1.13M R&D tax incentive from Australian govtDecember 11, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 25, 2023 | finance.yahoo.comImmutep receives ~A$1.13 million R&D Tax IncentiveOctober 24, 2023 | finance.yahoo.comImmutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023October 23, 2023 | stockhouse.comImmutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung CancerOctober 22, 2023 | markets.businessinsider.comImmutep : Efti+ Keytruda Generates Excellent OS Benefit In Phase II Trial In Metastatic NSCLCOctober 3, 2023 | finance.yahoo.comImmutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingSeptember 5, 2023 | finance.yahoo.comImmutep to Participate in September Investor ConferencesAugust 30, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Immutep (IMMP)August 3, 2023 | msn.comImmutep Limited - ADR (IMMP) Price Target Increased by 21.21% to 2.84August 1, 2023 | finance.yahoo.comImmutep Receives Positive Scientific Advice from European Medicines AgencyJune 20, 2023 | finance.yahoo.comImmutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3June 5, 2023 | benzinga.comImmutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual MeetingJune 3, 2023 | au.finance.yahoo.comIMMP - Immutep LimitedJune 2, 2023 | finance.yahoo.comImmutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement OfferMay 18, 2023 | msn.comMaxim Group Maintains Buy Rating for Immutep: Here's What You Need To KnowMay 18, 2023 | finance.yahoo.comImmutep (IMMP) Surges 65% on Upbeat Lung Cancer Study DataMay 17, 2023 | msn.comImmutep Soars with New Cancer TreatmentMay 17, 2023 | msn.comImmutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 TrialMay 16, 2023 | finance.yahoo.comImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung CancerSee More Headlines Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/11/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMMP CUSIPN/A CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+308.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio13.81 Quick Ratio13.81 Sales & Book Value Annual Sales$3.50 million Price / Sales52.26 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book2.00Miscellaneous Outstanding Shares87,930,000Free Float85,231,000Market Cap$182.89 million OptionableNot Optionable Beta2.21 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Marc Voigt (Age 50)CEO, MD, CFO, Chief Business Officer & Executive Director Comp: $367.95kMs. Deanne Miller LLB (Age 46)COO, General Counsel & Joint Company Secretary Comp: $240.62kDr. Frederic Triebel M.D. (Age 68)Ph.D., Chief Scientific Officer & Executive Director Comp: $293.73kMr. Christian Mueller BBAMSc., Senior Vice President of Regulatory & StrategyMr. Florian D. Vogl M.D.M.Sc., Ph.D., Chief Medical OfficerMs. Indira NaiduJoint Company SecretaryMore ExecutivesKey CompetitorsAstria TherapeuticsNASDAQ:ATXSVerastemNASDAQ:VSTMEsperion TherapeuticsNASDAQ:ESPRAldeyra TherapeuticsNASDAQ:ALDXApplied TherapeuticsNASDAQ:APLTView All CompetitorsInstitutional OwnershipOracle Investment Management Inc.Sold 377,961 shares on 11/14/2023Ownership: 0.587%Meridian Wealth Management LLCBought 48,150 shares on 10/17/2023Ownership: 0.354%View All Institutional Transactions IMMP Stock Analysis - Frequently Asked Questions Should I buy or sell Immutep stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMP shares. View IMMP analyst ratings or view top-rated stocks. What is Immutep's stock price target for 2024? 1 equities research analysts have issued 1-year target prices for Immutep's stock. Their IMMP share price targets range from $7.00 to $10.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 312.6% from the stock's current price. View analysts price targets for IMMP or view top-rated stocks among Wall Street analysts. How have IMMP shares performed in 2023? Immutep's stock was trading at $1.75 at the start of the year. Since then, IMMP shares have increased by 17.7% and is now trading at $2.06. View the best growth stocks for 2023 here. What other stocks do shareholders of Immutep own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT). Who are Immutep's major shareholders? Immutep's stock is owned by a variety of institutional and retail investors. Top institutional investors include Oracle Investment Management Inc. (0.59%), Meridian Wealth Management LLC (0.35%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Immutep? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IMMP) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.